Vulvar Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Vulvar Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Vulvar cancer is a rare type of cancer. It forms in a woman’s external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early.
The Vulvar Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Vulvar Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Vulvar Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 55 molecules, with 55 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Vulvar Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Vulvar Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Vulvar Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Agenus IncAkeso Inc
Alphamab Oncology
ApolloBio Corp
Ascendis Pharma AS
AstraZeneca Plc
Beijing Health Guard Biotechnology Inc
Bristol-Myers Squibb Co
CanWell Pharma Inc
Chengdu Institute of Biological Products Co Ltd
eTheRNA Immunotherapies NV
F. Hoffmann-La Roche Ltd
Gene Surgery
Gilead Sciences Inc
GSK plc
Guangzhou BeBetter Medicine Technology Co Ltd
Hengrui Yuanzheng Biotechnology Co Ltd
Ikena Oncology Inc
Inovio Pharmaceuticals Inc
Invectys SA
ISA Pharmaceuticals BV
Johnson & Johnson
Marengo Therapeutics Inc
Merck & Co Inc
Merck KGaA
Merus NV
Novita Pharmaceuticals Inc
Nykode Therapeutics ASA
Ono Pharmaceutical Co Ltd
PDS Biotechnology Corp
Pieris Pharmaceuticals Inc
Precigen Inc
Privo Technologies Inc
RemeGen Co Ltd
Repare Therapeutics Inc
Shanghai Bovax Biotechnology Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Zerun Biotechnology Co Ltd
Sichuan Yingrui Pharmaceutical Technology Co Ltd
SinoCelltech Group Ltd
SQZ Biotechnologies Co
Starpax Biopharma Inc
Systimmune Inc
Transcenta Holding Ltd
Transgene SA
Vincerx Pharma Inc
Xencor Inc
Zhejiang Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Vulvar Cancer reports